Asia Pacific Sickle Cell Disease Treatment Market Size, Share & Industry Trends Analysis Report By Treatment (Blood Transfusion, Pharmacotherapy, and Bone Marrow Transplant), By End-Use (Hospitals, Specialty Clinics), By Country and Growth Forecast, 2023 - 2030

The Asia Pacific Sickle Cell Disease Treatment Market should witness market growth of 28.8% CAGR during the forecast period (2023-2030).

Growth of the market is also anticipated to be fuelled by the increasing approval of novel therapeutic medications for treating the condition. Additionally, rising government involvement in enhancing healthcare services and disease awareness is anticipated to fuel market expansion. The inaccessibility of medications in rural areas will present further possibilities for expanding the market in the coming years. Additionally, many hospitals and international organizations have also initiated several campaigns to raise awareness about hemoglobin deficiency.

The sickle cell disease pipeline consists of large pharmaceutical corporations with novel drugs in clinical trials and mid-sized and minor pharmaceutical companies with early-stage pipeline products. Due to the high efficacy of these treatments in early clinical studies, regulatory agencies have a favourable opinion of them, thereby aiding the rapid development of these medications by their vendors. Recent technological developments and the identification of sickle cell disease also fuel the strong pipeline for treating sickle cell disorders.

According to the International Trade Administration, China's healthcare sector grew strongly in 2018 and experienced dynamic regulatory change. China's demand for medical devices reached USD 78.81 billion. In 2018, sales of pharmaceutical and health products totalled USD 219.91 billion. The demand for medical devices has maintained a double-digit increase for over a decade, making it one of China's fastest-growing product sectors. Over 70% of this rise was attributed to hospital procurement. Access to improved medical facilities and specialized care has improved the diagnosis and treatment of SCD in the Asia-Pacific region.

The China market dominated the Asia Pacific Sickle Cell Disease Treatment Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $547.4 Million by 2030. The Japan market is registering a CAGR of 28% during (2023-2030). Additionally, India's market would showcase a CAGR of 29.6% during (2023-2030).

Based on Treatment, the market is segmented into Blood Transfusion, Pharmacotherapy, and Bone Marrow Transplant. Based on End-Use, the market is segmented into Hospitals, Specialty Clinics and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Novartis AG, Pfizer Inc., bluebird bio, Inc., CSL Limited, Emmaus Life Sciences, Inc., Bristol Myers Squibb Company, CRISPR Therapeutics AG, Agios Pharmaceuticals, Inc. (LES LABORATOIRES SERVIER SAS), Novo Nordisk A/S and Medunik USA (Duchesnay Inc.).

Scope of the Study

By Treatment

• Blood Transfusion
• Pharmacotherapy
• Bone Marrow Transplant

By End-Use

• Hospitals
• Specialty Clinics
• Others

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• Novartis AG
• Pfizer Inc.
• bluebird bio, Inc.
• CSL Limited
• Emmaus Life Sciences, Inc.
• Bristol Myers Squibb Company
• CRISPR Therapeutics AG
• Agios Pharmaceuticals, Inc. (LES LABORATOIRES SERVIER SAS)
• Novo Nordisk A/S
• Medunik USA (Duchesnay Inc.)

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free